

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

VOLUNTARY ANNOUNCEMENT
PROPOSED CHANGE IN SHAREHOLDING

This announcement is made by Sisram Medical Ltd (the “**Company**”) on a voluntary basis.

On 30 September 2019, the board of directors of the Company (the “**Board**”) was notified by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (“**Fosun Pharma**”), a controlling shareholder of the Company, that Ample Up limited (“**Ample Up**”), a wholly-owned subsidiary of Fosun Pharma and a substantial shareholder of the Company, had entered into a sale and purchase agreement on that date with Magnificent View Investments Limited (“**Magnificent View**”) pursuant to which Ample Up agreed to acquire all of the shareholding interests held by Magnificent View in the Company, being 96,976,000 shares, which represent approximately 21.93% of the total issued shares of the Company as at the date of this announcement (the “**Proposed Acquisition**”). Completion of the Proposed Acquisition is subject to the satisfaction of certain conditions.

As at the date of this announcement, Fosun Pharma, through its wholly-owned subsidiaries, Ample Up and Chindex Medical Limited, holds 233,582,800 shares of the Company, representing approximately 52.83% of the total issued shares of the Company. Immediately following the completion of the Proposed Acquisition, Fosun Pharma, through its wholly-owned subsidiaries, will hold 330,558,800 shares of the Company, which represent approximately 74.76% of the total issued shares of the Company.

On Behalf of the Board
Sisram Medical Ltd
Yi LIU
Chairman

Hong Kong, 30 September 2019

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as Executive Directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Kun DAI as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.

* *for identification purpose only*